Search Browse Earnings

Kiniksa Pharmaceuticals International, plc

Nasdaq:KNSA

Pharmaceutical Preparations·LONDON

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Kiniksa Pharmaceuticals International, plc — SlamSEC

Revenue

$270.3M

+22.7% YoY

FY 2025

Adj. EBITDA

-$22.9M

-8.5% margin

FY 2025

Net Income

$14.1M

5.2% margin

FY 2025

EPS (Diluted)

$0.20

FY 2025

Stock Price

$45.78

-0.6%

2026-03-13

52W Range

$18.25 – $49.12

P/E Ratio

228.9x

Market Cap

—

Cash

$183.6M

FY 2025

Total Debt

—

Net Cash

$183.6M

FY 2025

Enterprise Value

—

Debt / EBITDA

8.0x

FY 2025

EV / EBITDA

—

Employees

—